PubRank

David Bowen

Author PubWeight™ 43.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012 8.12
2 Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013 6.50
3 A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011 3.28
4 Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011 3.12
5 Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013 2.97
6 Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009 1.78
7 The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008 1.52
8 Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006 1.43
9 Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005 1.41
10 Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2009 1.39
11 Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013 1.36
12 No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 2004 1.27
13 The lumicins: novel bacteriocins from Photorhabdus luminescens with similarity to the uropathogenic-specific protein (USP) from uropathogenic Escherichia coli. FEMS Microbiol Lett 2002 1.04
14 Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 2010 1.02
15 Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol 2013 0.99
16 Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 2008 0.98
17 Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Ann Hematol 2012 0.91
18 Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol 2014 0.84
19 Genetics of inositol polyphosphates. Subcell Biochem 2006 0.83
20 Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. Biores Open Access 2012 0.79
21 Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology. Br J Haematol 2002 0.79
22 Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal. Pharmacoeconomics 2013 0.78
23 Thalidomide therapy for low-risk Myelodysplasia. Leuk Res 2005 0.77
24 Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol 2014 0.77
25 Mitochondrial oxygen consumption and ineffective haematopoiesis in patients with myelodysplastic syndromes. Br J Haematol 2002 0.76
26 Micromegakaryocytes in CSF. Br J Haematol 2011 0.75
27 Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia. Haematologica 2006 0.75
28 Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress? Haematologica 2003 0.75